Viatris, Inc. Hits New 52-Week High of USD 17.66

Viatris, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 17.66 on July 17, 2026. This achievement marks a remarkable 64.51% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 18.43% during the same period. With a market capitalization of USD 15,347 million, Viatris operates in a competitive industry characterized by innovation and growth. The company's financial metrics reveal a dividend yield of 84.69%, indicating a strong return to shareholders despite its current loss-making status, as reflected by the absence of a price-to-earnings ratio. Additionally, Viatris maintains a debt-to-equity ratio of 0.89, suggesting a balanced approach to leveraging its capital structure. The stock's previous 52-week low was recorded at USD 8.63, highlighting the significant upward trajectory it has experienced. This performance underscores Viatris's position within the market and its ability to navigate the complexities of the pharmaceutical landscape.